These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 28404374)

  • 1. Generation of tricyclic imidazo[1,2-a]pyrazines as novel PI3K inhibitors by application of a conformational restriction strategy.
    Martínez González S; Rodríguez-Arístegui S; Hernández AI; Varela C; González Cantalapiedra E; Álvarez RM; Rodríguez Hergueta A; Bischoff JR; Albarrán MI; Cebriá A; Cendón E; Cebrián D; Alfonso P; Pastor J
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2536-2543. PubMed ID: 28404374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR.
    Martínez González S; Hernández AI; Varela C; Lorenzo M; Ramos-Lima F; Cendón E; Cebrián D; Aguirre E; Gomez-Casero E; Albarrán MI; Alfonso P; García-Serelde B; Mateos G; Oyarzabal J; Rabal O; Mulero F; Gonzalez-Granda T; Link W; Fominaya J; Barbacid M; Bischoff JR; Pizcueta P; Blanco-Aparicio C; Pastor J
    Bioorg Med Chem Lett; 2012 Aug; 22(16):5208-14. PubMed ID: 22819764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of novel PI3K inhibitors through a scaffold hopping strategy.
    Martínez González S; Hernández AI; Álvarez RM; Rodríguez A; Ramos-Lima F; Bischoff JR; Albarrán MI; Cebriá A; Hernández-Encinas E; García-Arocha J; Cebrián D; Blanco-Aparicio C; Pastor J
    Bioorg Med Chem Lett; 2017 Nov; 27(21):4794-4799. PubMed ID: 29017786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imidazo[1,2-a]pyrazines as novel PI3K inhibitors.
    Martínez González S; Hernández AI; Varela C; Rodríguez-Arístegui S; Alvarez RM; García AB; Lorenzo M; Rivero V; Oyarzabal J; Rabal O; Bischoff JR; Albarrán M; Cebriá A; Alfonso P; Link W; Fominaya J; Pastor J
    Bioorg Med Chem Lett; 2012 Mar; 22(5):1874-8. PubMed ID: 22325943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioisosteric approach to the discovery of imidazo[1,2-a]pyrazines as potent Aurora kinase inhibitors.
    Meng Z; Kulkarni BA; Kerekes AD; Mandal AK; Esposite SJ; Belanger DB; Reddy PA; Basso AD; Tevar S; Gray K; Jones J; Smith EB; Doll RJ; Siddiqui MA
    Bioorg Med Chem Lett; 2011 Jan; 21(1):592-8. PubMed ID: 21075632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of potent, selective and orally bioavailable imidazo[1,5-a]pyrazine derived ACK1 inhibitors.
    Jin M; Wang J; Kleinberg A; Kadalbajoo M; Siu KW; Cooke A; Bittner MA; Yao Y; Thelemann A; Ji Q; Bhagwat S; Mulvihill KM; Rechka JA; Pachter JA; Crew AP; Epstein D; Mulvihill MJ
    Bioorg Med Chem Lett; 2013 Feb; 23(4):979-84. PubMed ID: 23317569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel imidazo[1,2-a]pyrazin-8-amines as Brk/PTK6 inhibitors.
    Zeng H; Belanger DB; Curran PJ; Shipps GW; Miao H; Bracken JB; Arshad Siddiqui M; Malkowski M; Wang Y
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5870-5. PubMed ID: 21855335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and optimization of a series of imidazo[4,5-b]pyrazine derivatives as highly potent and exquisitely selective inhibitors of the mesenchymal-epithelial transition factor (c-Met) protein kinase.
    Zhao F; Zhang J; Zhang L; Hao Y; Shi C; Xia G; Yu J; Liu Y
    Bioorg Med Chem; 2016 Sep; 24(18):4281-4290. PubMed ID: 27448775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of ETP-46321, a potent and orally bioavailable PI3K α, δ inhibitor.
    Martínez González S; Hernández AI; Varela C; Rodríguez-Arístegui S; Lorenzo M; Rodríguez A; Rivero V; Martín JI; Saluste CG; Ramos-Lima F; Cendón E; Cebrián D; Aguirre E; Gomez-Casero E; Albarrán M; Alfonso P; García-Serelde B; Oyarzabal J; Rabal O; Mulero F; Gonzalez-Granda T; Link W; Fominaya J; Barbacid M; Bischoff JR; Pizcueta P; Pastor J
    Bioorg Med Chem Lett; 2012 May; 22(10):3460-6. PubMed ID: 22520259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of a novel aminopyrazine series as selective PI3Kα inhibitors.
    Barlaam B; Cosulich S; Fitzek M; Germain H; Green S; Hanson LL; Harris CS; Hancox U; Hudson K; Lambert-van der Brempt C; Lamorlette M; Magnien F; Ouvry G; Page K; Ruston L; Ward L; Delouvrié B
    Bioorg Med Chem Lett; 2017 Jul; 27(13):3030-3035. PubMed ID: 28526367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326).
    Heffron TP; Heald RA; Ndubaku C; Wei B; Augistin M; Do S; Edgar K; Eigenbrot C; Friedman L; Gancia E; Jackson PS; Jones G; Kolesnikov A; Lee LB; Lesnick JD; Lewis C; McLean N; Mörtl M; Nonomiya J; Pang J; Price S; Prior WW; Salphati L; Sideris S; Staben ST; Steinbacher S; Tsui V; Wallin J; Sampath D; Olivero AG
    J Med Chem; 2016 Feb; 59(3):985-1002. PubMed ID: 26741947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.
    Belanger DB; Williams MJ; Curran PJ; Mandal AK; Meng Z; Rainka MP; Yu T; Shih NY; Siddiqui MA; Liu M; Tevar S; Lee S; Liang L; Gray K; Yaremko B; Jones J; Smith EB; Prelusky DB; Basso AD
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6739-43. PubMed ID: 20855207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.
    Belanger DB; Curran PJ; Hruza A; Voigt J; Meng Z; Mandal AK; Siddiqui MA; Basso AD; Gray K
    Bioorg Med Chem Lett; 2010 Sep; 20(17):5170-4. PubMed ID: 20674350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potency switch between CHK1 and MK2: discovery of imidazo[1,2-a]pyrazine- and imidazo[1,2-c]pyrimidine-based kinase inhibitors.
    Meng Z; Ciavarri JP; McRiner A; Zhao Y; Zhao L; Reddy PA; Zhang X; Fischmann TO; Whitehurst C; Arshad Siddiqui M
    Bioorg Med Chem Lett; 2013 May; 23(10):2863-7. PubMed ID: 23587425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of isoform selective PI3-kinase inhibitors as pharmacological tools for elucidating the PI3K pathway.
    Bruce I; Akhlaq M; Bloomfield GC; Budd E; Cox B; Cuenoud B; Finan P; Gedeck P; Hatto J; Hayler JF; Head D; Keller T; Kirman L; Leblanc C; Le Grand D; McCarthy C; O'Connor D; Owen C; Oza MS; Pilgrim G; Press NE; Sviridenko L; Whitehead L
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5445-50. PubMed ID: 22863202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imidazo[1,2-a]pyrazine, Imidazo[1,5-a]quinoxaline and Pyrazolo[1,5-a]quinoxaline derivatives as IKK1 and IKK2 inhibitors.
    Patinote C; Bou Karroum N; Moarbess G; Deleuze-Masquefa C; Hadj-Kaddour K; Cuq P; Diab-Assaf M; Kassab I; Bonnet PA
    Eur J Med Chem; 2017 Sep; 138():909-919. PubMed ID: 28750313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479.
    Robarge KD; Lee W; Eigenbrot C; Ultsch M; Wiesmann C; Heald R; Price S; Hewitt J; Jackson P; Savy P; Burton B; Choo EF; Pang J; Boggs J; Yang A; Yang X; Baumgardner M
    Bioorg Med Chem Lett; 2014 Oct; 24(19):4714-4723. PubMed ID: 25193232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent and selective inhibitors of PI3Kδ: obtaining isoform selectivity from the affinity pocket and tryptophan shelf.
    Sutherlin DP; Baker S; Bisconte A; Blaney PM; Brown A; Chan BK; Chantry D; Castanedo G; DePledge P; Goldsmith P; Goldstein DM; Hancox T; Kaur J; Knowles D; Kondru R; Lesnick J; Lucas MC; Lewis C; Murray J; Nadin AJ; Nonomiya J; Pang J; Pegg N; Price S; Reif K; Safina BS; Salphati L; Staben S; Seward EM; Shuttleworth S; Sohal S; Sweeney ZK; Ultsch M; Waszkowycz B; Wei B
    Bioorg Med Chem Lett; 2012 Jul; 22(13):4296-302. PubMed ID: 22672799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of benzo[4,5]imidazo[1,2-c]pyrimidine and benzo[4,5]imidazo[1,2-a]pyrazine derivatives as anaplastic lymphoma kinase inhibitors.
    Tardy S; Orsato A; Mologni L; Bisson WH; Donadoni C; Gambacorti-Passerini C; Scapozza L; Gueyrard D; Goekjian PG
    Bioorg Med Chem; 2014 Feb; 22(4):1303-12. PubMed ID: 24468632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase.
    Mortensen DS; Sapienza J; Lee BG; Perrin-Ninkovic SM; Harris R; Shevlin G; Parnes JS; Whitefield B; Hickman M; Khambatta G; Bisonette RR; Peng S; Gamez JC; Leisten J; Narla RK; Fultz KE; Sankar S
    Bioorg Med Chem Lett; 2013 Mar; 23(6):1588-91. PubMed ID: 23414803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.